Risk factors

Lineage Cell Therapeutics (LCTX) risk factors

Item 1A of every Lineage Cell Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open LCTX in Gloomberb →
  • FY2025 10-K risk factors

    87 risks, 25 new, 13 dropped, 23 reworded since the prior year. Company faces clinical and regulatory hurdles for nascent allogeneic cell therapies requiring surgical delivery. R&D spending increased to $17.7 million in 2025.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors

    75 risks. Company is heavily reliant on Roche for OpRegen development and revenue.

    Filed Mar 10, 2025